Cell transplantation for the treatment of Parkinson's disease

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Cell transplantation is an experimental therapy for Parkinson's disease (PD) and other movement disorders. Several open-label research trials have shown clinically meaningful improvement in parkinsonian signs and symptoms after striatal transplantation of allogeneic fetal ventral mesencephalic (FVM) tissue. However, ethical concerns, variability in surgical techniques, and reports of unusual late complications in a few patients in a clinical trial have limited the use of allogeneic FVM tissue to a few research centers. Research into alternative cell sources such as porcine FVM and allogeneic retinal pigment epithelial cells has shown promising results in preclinical trials, and they are currently being tested in clinical trials. Novel strategies to improve cell survival and to avoid immune rejection of transplants show promising results in preclinical trials. This article focuses on these recent advances and compares the potential clinical utility of these emerging cell therapies for the treatment of advanced PD.

Original languageEnglish (US)
Pages (from-to)103-115
Number of pages13
JournalSeminars in Neurology
Volume21
Issue number1
DOIs
StatePublished - May 9 2001

Fingerprint

Cell Transplantation
Parkinson Disease
Research
Clinical Trials
Corpus Striatum
Investigational Therapies
Retinal Pigments
Homologous Transplantation
Movement Disorders
Graft Rejection
Parkinsonian Disorders
Cell- and Tissue-Based Therapy
Signs and Symptoms
Cell Survival
Swine
Therapeutics
Epithelial Cells

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

@article{08368959a7084dfcbea1ebc0f2e0968b,
title = "Cell transplantation for the treatment of Parkinson's disease",
abstract = "Cell transplantation is an experimental therapy for Parkinson's disease (PD) and other movement disorders. Several open-label research trials have shown clinically meaningful improvement in parkinsonian signs and symptoms after striatal transplantation of allogeneic fetal ventral mesencephalic (FVM) tissue. However, ethical concerns, variability in surgical techniques, and reports of unusual late complications in a few patients in a clinical trial have limited the use of allogeneic FVM tissue to a few research centers. Research into alternative cell sources such as porcine FVM and allogeneic retinal pigment epithelial cells has shown promising results in preclinical trials, and they are currently being tested in clinical trials. Novel strategies to improve cell survival and to avoid immune rejection of transplants show promising results in preclinical trials. This article focuses on these recent advances and compares the potential clinical utility of these emerging cell therapies for the treatment of advanced PD.",
author = "Thyagarajan Subramanian",
year = "2001",
month = "5",
day = "9",
doi = "10.1055/s-2001-13125",
language = "English (US)",
volume = "21",
pages = "103--115",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "1",

}

Cell transplantation for the treatment of Parkinson's disease. / Subramanian, Thyagarajan.

In: Seminars in Neurology, Vol. 21, No. 1, 09.05.2001, p. 103-115.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cell transplantation for the treatment of Parkinson's disease

AU - Subramanian, Thyagarajan

PY - 2001/5/9

Y1 - 2001/5/9

N2 - Cell transplantation is an experimental therapy for Parkinson's disease (PD) and other movement disorders. Several open-label research trials have shown clinically meaningful improvement in parkinsonian signs and symptoms after striatal transplantation of allogeneic fetal ventral mesencephalic (FVM) tissue. However, ethical concerns, variability in surgical techniques, and reports of unusual late complications in a few patients in a clinical trial have limited the use of allogeneic FVM tissue to a few research centers. Research into alternative cell sources such as porcine FVM and allogeneic retinal pigment epithelial cells has shown promising results in preclinical trials, and they are currently being tested in clinical trials. Novel strategies to improve cell survival and to avoid immune rejection of transplants show promising results in preclinical trials. This article focuses on these recent advances and compares the potential clinical utility of these emerging cell therapies for the treatment of advanced PD.

AB - Cell transplantation is an experimental therapy for Parkinson's disease (PD) and other movement disorders. Several open-label research trials have shown clinically meaningful improvement in parkinsonian signs and symptoms after striatal transplantation of allogeneic fetal ventral mesencephalic (FVM) tissue. However, ethical concerns, variability in surgical techniques, and reports of unusual late complications in a few patients in a clinical trial have limited the use of allogeneic FVM tissue to a few research centers. Research into alternative cell sources such as porcine FVM and allogeneic retinal pigment epithelial cells has shown promising results in preclinical trials, and they are currently being tested in clinical trials. Novel strategies to improve cell survival and to avoid immune rejection of transplants show promising results in preclinical trials. This article focuses on these recent advances and compares the potential clinical utility of these emerging cell therapies for the treatment of advanced PD.

UR - http://www.scopus.com/inward/record.url?scp=0035032552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035032552&partnerID=8YFLogxK

U2 - 10.1055/s-2001-13125

DO - 10.1055/s-2001-13125

M3 - Review article

C2 - 11346020

AN - SCOPUS:0035032552

VL - 21

SP - 103

EP - 115

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 1

ER -